The role of PTEN phosphorylation remodeling in hematopoietic stem cell regulation

PTEN磷酸化重塑在造血干细胞调控中的作用

基本信息

  • 批准号:
    8043552
  • 负责人:
  • 金额:
    $ 37.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-03-15 至 2014-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Our goal is to define the roles of Pten phosphorylation remodeling in hematopoietic stem cell (HSC) regulation. Pten, a tumor suppressor, has both lipid and protein phosphatase activities that inhibit PI3K/Akt and Fak-MAPK signaling respectively. It regulates many aspects of cell behavior, including proliferation, survival, adhesion and migration.1-4 The phosphatase activities of Pten are regulated by its c-terminal tail phosphorylation.5, 6 In addition, Pten many also have some phosphatase-independent functions. Many of Pten's biological functions are dependent upon protein-protein interactions which are mediated by its PDZ-motif.7 Knockout of Pten in mouse hematopoietic tissues results in abnormal activation of PI3K/Akt and Src signaling, which leads to uncontrolled HSC activation (G0 to G1 transition) and mobilization, followed by HSC decline. These mice develop myeloproliferative disorder (MPD) followed by acute myeloid/T lymphoid leukemia. Although Pten mutations are not commonly found in hematopoietic malignancies, including leukemia, p-Pten (the phosphorylated form of Pten) levels are increased in the abnormal blasts of most leukemic patients' bone marrow samples. Phosphorylation of Pten's c-terminal tail (ser380, thr382, and thr383) leads to a conformation change which may result in the blocking of its ability to bind to other partner proteins, the reduction of Pten phosphatase activity, and/or the alteration of the lifespan of the Pten protein. Our recent studies have suggested that the phosphorylation of Pten's c-terminal tail may not affect its lipid phosphatase activity but significantly compromises its protein phosphatase activity. The non-phosphorylated form of Pten (non-p-Pten) inhibits Src/Fak/p38 activity, thus repressing cell migration/invasiveness and inducing cell:cell contact inhibition of growth. p-Pten might have a dominant-negative function which induces cell-contact-related Src/Fak/p38 activation. We found that non-p-Pten is expressed in HSCs, while p- Pten levels are increased when HSCs enter the cell cycle; both of these events correspond to increased p- Src, p-Fak and p-p38 levels. Transduced over-expression of non-p-Pten preserves HSCs in a bone marrow niche-dependent manner, whereas transduced over-expression of p-Pten induces HSC/progenitors (HSC/Ps, from wild-type mice which have endogenous Pten expression) to differentiate to myeloid precursors. We propose that non-p-Pten maintains HSC quiescence and self-renewal ability through inducing cell:cell (HSCs and niche cells) contact-induced inhibition of growth by inhibiting Src/Fak/p38 signaling activities, whereas Pten's c-terminal phosphorylation alters its ability to bind to its partners and compromises its protein phosphatase activity. p-Pten promotes opposite functions to these through inducing cell:cell contact-related Src/Fak/p38 signaling. These studies will provide insights into how quiescent HSCs become activated and expand in number, and how we might be able to induce activated HSCs to revert back into quiescence in order to enhance their engraftment ability. This should greatly help our ability to expand HSCs in vitro and hence improve the outcome of clinical stem cell transplantation. It might be also help us to understand the nature of Pten c-terminal phosphorylation in leukemogenesis. PUBLIC HEALTH RELEVANCE: This proposed study will provide insights into how quiescent hematopoietic stem cell be induced cell cycle entry and proliferation, and how stem cell function is regulated by PTEN c-terminal phosphorylation. The predicted outcome will greatly help our ability to expand hematopoietic stem cells in vitro and hence improve the outcome of clinical stem cell transplantation.
描述(由申请人提供):我们的目标是确定Pten磷酸化重塑在造血干细胞(HSC)调节中的作用。Pten是一种肿瘤抑制因子,具有脂质和蛋白磷酸酶活性,分别抑制PI 3 K/Akt和Fak-MAPK信号转导。它调节细胞行为的许多方面,包括增殖、存活、粘附和迁移。1 -4 Pten的磷酸酶活性受其c-末端尾部磷酸化的调节。5,6此外,Pten许多还具有一些磷酸酶非依赖性功能。Pten的许多生物学功能依赖于由其PDZ基序介导的蛋白质-蛋白质相互作用。7小鼠造血组织中Pten的敲除导致PI 3 K/Akt和Src信号传导的异常活化,这导致不受控制的HSC活化(G 0至G1转变)和动员,随后是HSC下降。这些小鼠发生骨髓增生性疾病(MPD),随后发生急性髓样/T淋巴样白血病。尽管Pten突变在造血系统恶性肿瘤(包括白血病)中并不常见,但在大多数白血病患者骨髓样本的异常原始细胞中,p-Pten(Pten的磷酸化形式)水平升高。 Pten的C-末端尾(ser 380、thr 382和thr 383)的磷酸化导致构象变化,这可能导致其与其它配偶体蛋白结合的能力的阻断、Pten磷酸酶活性的降低和/或Pten蛋白的寿命的改变。我们最近的研究表明,Pten的C-末端尾的磷酸化可能不影响其脂质磷酸酶活性,但显着损害其蛋白磷酸酶活性。Pten的非磷酸化形式(非β-Pten)抑制Src/Fak/p38活性,从而抑制细胞迁移/侵袭并诱导细胞:细胞接触抑制生长。p-Pten可能具有显性负性功能,诱导细胞接触相关的Src/Fak/p38活化。我们发现,非-p-Pten在HSC中表达,而当HSC进入细胞周期时,p-Pten水平增加;这两个事件都对应于增加的p-Src、p-Fak和p-p38水平。非β-Pten的转导过表达以骨髓小生境依赖性方式保存HSC,而β-Pten的转导过表达诱导HSC/祖细胞(HSC/Ps,来自具有内源性Pten表达的野生型小鼠)分化为骨髓前体。 我们提出,non-p-Pten通过抑制Src/Fak/p38信号传导活性诱导细胞:细胞(HSC和小生境细胞)接触诱导的生长抑制来维持HSC的静止和自我更新能力,而Pten的C-末端磷酸化改变了其与其伴侣结合的能力并损害了其蛋白磷酸酶活性。p-Pten通过诱导细胞:细胞接触相关的Src/Fak/p38信号传导促进与这些相反的功能。 这些研究将提供关于静止的HSC如何被激活并在数量上扩大的见解,以及我们如何能够诱导激活的HSC恢复到静止状态以增强其移植能力。这将极大地帮助我们在体外扩增HSC的能力,从而改善临床干细胞移植的结果。这也有助于我们理解Pten C端磷酸化在白血病发生中的作用。 公共卫生相关性:这项研究将有助于深入了解静止造血干细胞是如何被诱导进入细胞周期和增殖的,以及干细胞功能是如何通过PTEN C-末端磷酸化调节的。预测的结果将大大有助于我们体外扩增造血干细胞的能力,从而提高临床干细胞移植的结果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jiwang Zhang其他文献

Jiwang Zhang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jiwang Zhang', 18)}}的其他基金

RIP1/RIP3-Calpain-Stat3 and NF-kappa B pathways in AML pathogenesis and treatment
RIP1/RIP3-Calpain-Stat3 和 NF-kappa B 通路在 AML 发病机制和治疗中的作用
  • 批准号:
    10401827
  • 财政年份:
    2018
  • 资助金额:
    $ 37.38万
  • 项目类别:
RIP1/RIP3-Calpain-Stat3 and NF-kappa B pathways in AML pathogenesis and treatment
RIP1/RIP3-Calpain-Stat3 和 NF-kappa B 通路在 AML 发病机制和治疗中的作用
  • 批准号:
    9922242
  • 财政年份:
    2018
  • 资助金额:
    $ 37.38万
  • 项目类别:
Systematic identification of hematopoietic stem cell expansion factors
造血干细胞扩增因子的系统鉴定
  • 批准号:
    9754241
  • 财政年份:
    2017
  • 资助金额:
    $ 37.38万
  • 项目类别:
The role of PTEN phosphorylation remodeling in hematopoietic stem cell regulation
PTEN磷酸化重塑在造血干细胞调控中的作用
  • 批准号:
    8387748
  • 财政年份:
    2010
  • 资助金额:
    $ 37.38万
  • 项目类别:
The role of PTEN phosphorylation remodeling in hematopoietic stem cell regulation
PTEN磷酸化重塑在造血干细胞调控中的作用
  • 批准号:
    7784548
  • 财政年份:
    2010
  • 资助金额:
    $ 37.38万
  • 项目类别:
The role of PTEN phosphorylation remodeling in hematopoietic stem cell regulation
PTEN磷酸化重塑在造血干细胞调控中的作用
  • 批准号:
    8197839
  • 财政年份:
    2010
  • 资助金额:
    $ 37.38万
  • 项目类别:
The role of PTEN phosphorylation remodeling in hematopoietic stem cell regulation
PTEN磷酸化重塑在造血干细胞调控中的作用
  • 批准号:
    8590215
  • 财政年份:
    2010
  • 资助金额:
    $ 37.38万
  • 项目类别:

相似海外基金

Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
  • 批准号:
    10655162
  • 财政年份:
    2023
  • 资助金额:
    $ 37.38万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10651543
  • 财政年份:
    2023
  • 资助金额:
    $ 37.38万
  • 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
  • 批准号:
    10829603
  • 财政年份:
    2023
  • 资助金额:
    $ 37.38万
  • 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
  • 批准号:
    10839678
  • 财政年份:
    2023
  • 资助金额:
    $ 37.38万
  • 项目类别:
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
预测儿童急性白血病甲氨蝶呤神经毒性的系统流行病学方法
  • 批准号:
    10655716
  • 财政年份:
    2023
  • 资助金额:
    $ 37.38万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10435886
  • 财政年份:
    2022
  • 资助金额:
    $ 37.38万
  • 项目类别:
mRNA stability and its impact on hematopoiesis and acute leukemia
mRNA稳定性及其对造血和急性白血病的影响
  • 批准号:
    10339742
  • 财政年份:
    2022
  • 资助金额:
    $ 37.38万
  • 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
  • 批准号:
    10505579
  • 财政年份:
    2022
  • 资助金额:
    $ 37.38万
  • 项目类别:
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemia
急性白血病微小残留病的克隆动力学和化疗耐药机制
  • 批准号:
    10351765
  • 财政年份:
    2022
  • 资助金额:
    $ 37.38万
  • 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
  • 批准号:
    10576955
  • 财政年份:
    2022
  • 资助金额:
    $ 37.38万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了